Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)

NCT ID: NCT00998309

Last Updated: 2012-05-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

502 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-10-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To collect the efficacy and safety information of Zithromax-SR related to their appropriate use in daily practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All the patients whom an investigator prescribes the first Azithromycin SR should be registered within 14 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Azithromycin SR

Patients taking Azithromycin.

Azithromycin SR

Intervention Type DRUG

Zithromax SR 2g, taking once for treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Azithromycin SR

Zithromax SR 2g, taking once for treatment.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zithromax SR, Azithromycin SR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects diagnosed with skin and soft tissue infection, sexually-transmitted infection, and infection of the oral.
* Subjects must have no prior experience with Azithromycin SR.

Exclusion Criteria

* Patients not administered Azithromycin SR.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A0661202

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cefixime / Azithromycin pK Study
NCT02708992 COMPLETED PHASE1
Zoliflodacin in Uncomplicated Gonorrhoea
NCT03959527 COMPLETED PHASE3
Skin Inflammation and PK of Azithromycin
NCT06170983 NOT_YET_RECRUITING NA